---
title: United Therapeutics CEO Martine Rothblatt Crosses B in Career Sales
type: news
slug: martine-rothblatt-united-therapeutics-uthr-insider-selling-1b
canonical_url: https://13finsight.com/news/martine-rothblatt-united-therapeutics-uthr-insider-selling-1b
published_at: 2026-05-01T07:21:40.828Z
updated_at: 2026-05-01T07:30:46.083Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 513
locale: en
source: 13F Insight
---

# United Therapeutics CEO Martine Rothblatt Crosses B in Career Sales

> Chairperson and CEO Martine Rothblatt has crossed a historic milestone of .05 billion in career sales as she continues her systematic diversification program in UTHR stock.

A Billion-Dollar Milestone in Systematic Diversification Martine Rothblatt, the Chairperson and CEO of UNITED THERAPEUTICS Corp (UTHR), has crossed a significant threshold in her career transaction history. With recent sales in April 2026, Rothblatt's total divestment from the company she founded has surpassed $1.05 billion. While a billion-dollar figure often suggests an exit, for Rothblatt, it represents the continuation of one of the most consistent 10b5-1 systematic programs in the biotech sector. Our data indicates that Rothblatt's latest transactions are almost exclusively Exercise-and-Sell (Code M + S) events. On April 27, 2026, she exercised 9,500 options at a strike price of $146.03 and immediately sold the resulting shares in the open market at prices ranging from $566 to $572. This pattern allows the CEO to realize compensatory gains while maintaining a core equity stake of over 110,000 shares directly. The 10b5-1 Blueprint: Consistency Over Conviction For 13F Insight users, the key to interpreting Rothblatt's activity is the cadence. Unlike discretionary sellers who may time their exits to quarterly results or pipeline news, Rothblatt's sales have occurred with mechanical regularity for years. This suggests that the transactions are driven by a long-term financial blueprint rather than a bearish view on United Therapeutics' future. The stock's performance—reaching recent highs near $570—validates the strength of the underlying business despite the systematic insider selling. Rothblatt's role as a pioneer in lung disease therapeutics and her aggressive push into organ manufacturing remain the primary drivers of investor sentiment. The fact that she remains at the helm with a multi-hundred-million-dollar stake suggests that her alignment with shareholders remains intact, even as she realizes the fruits of decades of leadership. Institutional Confidence and Holder Depth As Rothblatt diversifies, the institutional holder base of UTHR remains robust. The Vanguard Group recently reported a 5.19% stake, representing 2.27 million shares. Even more notable is the presence of WELLINGTON MANAGEMENT GROUP LLP, which holds a 5.70% stake valued at over $1.3 billion. These high-quality active managers provide a critical counter-balance to insider activity, suggesting that the institutional "smart money" remains bullish on the company's valuation. The concentration of institutional ownership among the top 5 filers provides a level of price support that has allowed the stock to absorb Rothblatt's systematic sales without significant volatility. For investors, the data confluence of stable institutional holding and predictable insider selling creates a transparent and relatively low-risk ownership narrative. What to Watch: Pipeline Catalysts and 13D Triggers While there are currently no active 13D activist filings for United Therapeutics, the company's high cash position and market-leading therapeutics make it a perennial candidate for institutional repositioning. Investors should monitor the UTHR Holder Page for any sudden changes in institutional concentration that might signal a shift in the status quo. As Rothblatt continues her systematic program, her career transaction history will remain a case study in how founders can achieve liquidity without destabilizing their company's market position. As long as the sales remain tied to option exercises and prearranged plans, the long-term thesis for United Therapeutics remains unchanged. Track Martine Rothblatt's full career trading history → Martine Rothblatt Profile

---

Source: 13F Insight — https://13finsight.com/news/martine-rothblatt-united-therapeutics-uthr-insider-selling-1b
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-05-01T07:30:46.083Z